ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Trends in male breast cancer in Spain, 1999-2023: a nationwide analysis of incidence and mortality.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMale breast cancer (MBC) is rare and increasing globally, with limited data on trends in Spain. The study examines MBC trends, incidence, and mortality over a 25 year period (1999-2023) to guide public health strategies.
methodsAn ecological trend study was conducted using national mortality data from the Spanish National Statistics Institute and modeled incidence estimates from the Global Burden of Disease Study 2023. Age-standardized incidence and mortality rates (ASIR and ASMR) per 100,000 men were calculated using the European Standard Population 2013. Joinpoint regression identified temporal inflection points. Age-Period-Cohort (APC) modeling quantified age, period, and cohort effects for men aged 30-84 years.
resultsThe study recorded 7594 MBC cases and 1,931 deaths. ASMR declined from 0.65 to 0.39 per 100,000 (AAPC - 1.8%), with significant declines from 1999-2006 (APC - 5.1%) and 2013-2023 (APC - 3.6%). ASIR remained largely stable (AAPC 0.1%), increasing slightly from 1999-2006 (APC + 1.7%) and declining thereafter (APC - 0.5%). The Mortality-to-Incidence Ratio decreased from 0.41 to 0.26. APC analysis demonstrated significant net declines in mortality (- 1.33%/year) and incidence (- 0.83%/year), primarily driven by period effects and lower risk among later birth cohorts. Mortality reductions were most pronounced among men aged 55-64 years.
conclusionMBC mortality in Spain has declined steadily, reflecting improvements in clinical management, while stable incidence indicates minimal change in disease occurrence. Continued focus on early detection, male-specific awareness, and adherence to guideline-based therapy is essential to further reduce the MBC burden.
Indexed as
Identifiers
41910709What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.